Medical Imaging Reagents Key Players, Recent Strategic Partnerships, Operational Excellence, Deal Structuring, Patent Expansions

Medical Imaging Reagents Market Size Forecast and Companies

The global medical imaging reagents market size was predicted at US$ 11.25 billion in 2023 and is projected to grow to US$ 19.32 billion by 2034, rising at a compound annual growth rate (CAGR) of 5.04% from 2024 to 2034.

Top companies in the Medical Imaging Reagents are:

• Thermo Fisher Scientific Inc.
• Canon Medical Systems Corporation
• Fujifilm
• GE Healthcare
• Siemens Healthineers
• Hitachi Medical
• Hologic
• Philips Healthcare
• Roche
• Carestream Health
• Qiagen
• Abbott Laboratories

Latest Announcements by Industry Leaders

• In October 2024, Kevin O’Neill, president and CEO of the Pharmaceutical Diagnostics Segment at GE Healthcare, reported that phase I clinical trial results of macrocyclic manganese-based MRI contrast agent are a reminder of Norway’s heritage of innovation shaping the field of diagnostic imaging and improving patient outcomes globally.
• In May 2024, Tai Fujita, vice president of the endoscopy division at Fujifilm Healthcare Americas Corporation, announced that the company aims to deliver the best possible endoscopic imaging solutions to meet the growing needs of customers and offer the brilliant experience of image clarity and performance to industry experts.
• In February 2024, Tanja Brycker, vice president of strategic development, breast and skeletal health, and gynecological surgical solutions at Hologic, reported that research and education are central pillars of Hologic’s innovation, which supports radiologists to achieve better patient outcomes. It was also reported that Hologic continues its collaboration with Bayer on contrast-enhanced mammography.

Recent Development in the Medical Imaging Reagents Market

• In October 2024, GE Healthcare announced its phase I clinical trial results of macrocyclic manganese-based MRI contrast agent, which is clinically relevant with no serious adverse events and could be an alternative to gadolinium-based contrast agents.
• In May 2024, Fujifilm announced the commercialization of two novel endoscopic imaging technologies named CAD EYE and SCALE EYE at the Digestive Disease Week 2024 Conference. These two new technologies enable the real-time detection of colonic mucosal lesions while performing colonoscopy procedures.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com